TIVA vs Inhalational Anesthesia: VITAL Trial and USMLE Review

The largest trial to date comparing the two main techniques of general anesthesia in the NHS found no meaningful difference in recovery between them. The VITAL trial randomized 2,507 adults aged 50 and older having major planned noncardiac surgery to either total intravenous anesthesia (TIVA) with propofol or volatile inhaled anesthesia. The results were published in JAMA, and the authors conclude that the choice can continue to rest on patient and clinician preference.

What happened

VITAL was led by the University of Warwick and The Royal Marsden NHS Foundation Trust and enrolled patients at 49 NHS hospitals. Participants were randomly allocated to one of two approaches:

• TIVA: a continuous infusion of propofol.
• Inhalational anesthesia: volatile gases such as sevoflurane or isoflurane.

The primary outcome was the number of days patients were alive and out of hospital 30 days after surgery. There was no meaningful difference between the groups.

Secondary findings pointed the same way. Major complications, delirium and death at 30 days, 90 days and six months were similar. The one signal favoring TIVA was in early comfort: on the day after surgery, TIVA patients reported lower rates of thirst, hoarseness, nausea and vomiting. The investigators describe this as a modest improvement in early postoperative recovery and comfort.

A separate economic evaluation in Anaesthesia found similar costs to the NHS and similar quality of life over six months. Together, the two papers suggest the techniques are clinically and economically equivalent for adults having major noncardiac surgery.

Why it matters

More than 1.5 million major noncardiac operations are performed in the U.K. each year, and both techniques are used routinely. Some anesthesiologists have argued that TIVA gives a smoother recovery, with less sickness and pain. Others have pointed to rare risks such as a patient briefly regaining awareness during surgery. According to the source, no large U.K. trial had previously settled which technique, if either, was better.

A well-conducted "null" result is useful. It means health systems have no strong outcome-based reason to mandate one technique. In the words of chief investigator Joyce Yeung, doctors can decide "based on what's right for the person in front of them, not on pressure to switch to a newer or supposedly superior technique."

For exam preparation, the trial also illustrates several recurring Step 1 and Step 2 CK themes. These include pharmacology of anesthetics, postoperative nausea and vomiting, and how to interpret a randomized trial that finds no difference.

What to know for the USMLE — high-yield review

The following is textbook background, not data from the trial.

• Propofol mechanism: it potentiates GABA-A receptor activity, increasing chloride influx and hyperpolarizing the neuron. It has very rapid onset and offset because of redistribution from brain to other tissues.
• Propofol adverse effects: dose-dependent hypotension and respiratory depression, and pain on injection. It is formulated in a lipid emulsion, which can contribute to hypertriglyceridemia with prolonged use. Propofol infusion syndrome (metabolic acidosis, rhabdomyolysis, cardiac failure) is a rare complication of prolonged high-dose infusion.
• Propofol and nausea: propofol has antiemetic properties, which is a plausible pharmacologic background for the lower nausea and vomiting seen with TIVA in VITAL. It also lowers cerebral blood flow and intracranial pressure.
• Volatile anesthetics: sevoflurane, isoflurane, desflurane (and older halothane). They cause dose-dependent vasodilation and hypotension, reduce the ventilatory response to hypoxia and hypercapnia, and can raise cerebral blood flow.
• Potency and speed: MAC (minimum alveolar concentration) is the concentration that prevents movement in 50% of patients in response to a surgical stimulus. Lower MAC means higher potency, which correlates with higher lipid solubility (oil:gas partition coefficient). A low blood:gas partition coefficient means faster induction and recovery. Desflurane and nitrous oxide are the classic "fast" agents.
• Malignant hyperthermia: volatile anesthetics (and succinylcholine) can trigger it in patients with RYR1 variants. Features are hyperthermia, rigidity, hypercarbia and rhabdomyolysis. Treatment is dantrolene, which blocks sarcoplasmic reticulum calcium release. TIVA avoids the volatile trigger, which is why it is the usual choice in susceptible patients.
• Agent-specific toxicities: halothane causes hepatitis, methoxyflurane is nephrotoxic, and enflurane can lower the seizure threshold.
• PONV: risk factors in the Apfel score are female sex, nonsmoker, history of PONV or motion sickness, and postoperative opioids. Volatile agents and nitrous oxide add risk. Antiemetic classes include 5-HT3 antagonists (ondansetron), dexamethasone, dopamine antagonists (droperidol), NK1 antagonists (aprepitant) and scopolamine.
• Study design: the primary endpoint, "days alive and out of hospital," is a composite, patient-centered outcome. A trial with a null primary result and an open-label design is a common vignette setting for observer and reporting bias in subjective outcomes.

Limitations

The investigators list several limitations, and they matter for interpreting the secondary findings.

• The trial was not blinded. This could influence patient-reported outcomes such as pain and nausea. The nausea, thirst and hoarseness differences in favor of TIVA rest on self-report, so they should be read cautiously.
• All participants were treated within the NHS. The findings may not transfer directly to other health systems.
• Longer-term cancer outcomes were not examined.
• Environmental impact was not examined. This is an area of growing interest because volatile anesthetic gases are potent greenhouse gases.

Some further points follow from the design. The population was adults aged 50 and older undergoing major planned noncardiac surgery, so the results do not speak to children, cardiac surgery or emergency operations. The source also does not report subgroup analyses or the rate of rare events such as intraoperative awareness, so readers should check the full JAMA paper (Jhanji et al., DOI: 10.1001/jama.2026.11065) for those details. Secondary outcomes are generally considered hypothesis-generating.

FAQ

Is TIVA better than inhaled anesthesia?

Not on the main measure. In VITAL, days alive and out of hospital at 30 days were not meaningfully different. Complications, delirium and death were also similar through six months. TIVA was associated with less thirst, hoarseness, nausea and vomiting on the first postoperative day.

Which drugs were compared in the VITAL trial?

TIVA used a continuous propofol infusion. The comparison group received volatile gases such as sevoflurane or isoflurane. Participants were adults aged 50 or older having major planned noncardiac surgery.

How does this relate to PONV on the USMLE?

Volatile anesthetics are a recognized risk factor for postoperative nausea and vomiting, and propofol has antiemetic properties. VITAL found less nausea and vomiting with TIVA on postoperative day one, consistent with that background. Because the trial was unblinded, the self-reported differences should be interpreted with caution.

Key takeaways

• In 2,507 adults aged 50 or older having major noncardiac surgery, TIVA and volatile anesthesia gave similar recovery, complications, mortality, costs and quality of life.
• TIVA patients reported less thirst, hoarseness, nausea and vomiting on postoperative day one, but the trial was not blinded, so these self-reported findings need cautious interpretation.
• For the USMLE, know propofol (GABA-A, redistribution, hypotension, propofol infusion syndrome), volatile agents (MAC, partition coefficients, malignant hyperthermia) and PONV risk factors and treatment.